# PT-141 FAQ: Approval, Mechanism, Dosing & the Evidence > PT-141 (bremelanotide) FAQ: is it FDA-approved, is it legal, how it works, what receptors it hits, the approved dose, and how it differs from PDE-5 inhibitors — answered and cited. Direct answers on approval, legality, mechanism, and the approved dose — each drawn from the published record. ## Is PT-141 the same as bremelanotide? Yes — PT-141 is the development/lab name and bremelanotide is the international nonproprietary name (INN) for the same molecule, a synthetic cyclic heptapeptide that agonizes melanocortin receptors (chiefly MC4R/MC3R) in the central nervous system [1][7]. "PT-141" tends to denote the research-grade peptide; "bremelanotide" denotes the approved drug — same chemistry, different regulatory standing. ## What is bremelanotide? Bremelanotide is a melanocortin receptor agonist — a synthetic analogue of the hormone alpha-MSH — that acts centrally to increase sexual desire [1]. The FDA approved it in 2019 for low sexual desire causing distress (HSDD) in premenopausal women [7]. It is given as a 1.75 mg subcutaneous injection, as needed [7]. ## What is the approved bremelanotide dose? The approved dose is 1.75 mg injected subcutaneously, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than eight doses per month [7]. This is the label-attested dose for the approved HSDD indication; it is reported here as a record, not a recommendation. ## Is PT-141 approved for men? No. The FDA approval covers premenopausal women with HSDD only [7]. PT-141 was studied in men with erectile dysfunction — early systemic work produced dose-dependent erectile activity, and an intranasal program reached Phase IIb — but none of that led to approval in men [1][10]. Use in men is off-label and investigational. ## Is PT-141 FDA-approved? Yes, as bremelanotide (NDA 210557, approved June 21, 2019), but only for acquired, generalized HSDD in premenopausal women [7]. It is not approved for men, postmenopausal women, or performance. Material sold as a "PT-141 research chemical" sits outside this approval entirely [7]. ## Is PT-141 legal in the US? The approved drug, bremelanotide, is a lawful prescription medicine for its approved indication [7]. Material sold as "PT-141 research chemical" is offered for laboratory research use and is not for human consumption, and it is not subject to the identity and purity controls that apply to an approved pharmaceutical [7]. The two have different legal standing despite the shared lab name. ## Can you get PT-141 through telehealth? This site does not sell, source, or facilitate access to PT-141, and it does not assess any telehealth provider. As a regulatory note: bremelanotide is a prescription drug for its approved HSDD indication, so any legitimate route to the approved drug runs through a licensed prescriber [7]. Research-grade "PT-141" is a separate, unregulated category [7]. ## What is PT-141? PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that activates central melanocortin receptors (mainly MC4R) to increase sexual desire [1]. It acts on the brain, not on blood vessels, which distinguishes it from erection-focused blood-flow drugs [1]. It is FDA-approved for HSDD in premenopausal women [7]. ## What is PT-141 peptide? The PT-141 peptide is bremelanotide: sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, molecular weight ~1025 Da, a cyclic ring of seven amino acids [7]. The "cyclo" lactam bridge makes it more stable than a straight-chain peptide. It is a synthetic analogue of the natural melanocortin hormone alpha-MSH [1]. ## What does the PT-141 peptide do? It switches on melanocortin receptors (MC4R/MC3R) in brain circuits tied to sexual motivation, which increases sexual desire [1]. In trials in premenopausal women with HSDD it produced a small, statistically significant rise in desire and a drop in desire-related distress [3]. Brain imaging confirmed the effect is central [5]. ## What is PT-141 used for? Its one approved use is acquired, generalized HSDD — distressing low sexual desire — in premenopausal women [7]. It has been studied off-label and investigationally for erectile dysfunction in men and explored in metabolic research, but those are not approved uses [1][10]. This site keeps approved and off-label uses clearly separated. ## How does PT-141 work? PT-141 acts as an agonist at central melanocortin receptors, chiefly MC4R in hypothalamic circuits such as the medial preoptic area, engaging dopamine signaling tied to sexual desire [1][2]. It is a central mechanism — it does not work on vascular blood flow the way PDE-5 inhibitors do [1]. fMRI evidence shows it changes how the brain processes sexual cues [5]. ## What receptors does PT-141 act on? Chiefly the melanocortin 4 receptor (MC4R), with secondary activity at the melanocortin 3 receptor (MC3R), both concentrated in the central nervous system [1]. At higher or frequent dosing it can also activate peripheral MC1R, which is the basis for reported skin hyperpigmentation [7]. ## Does PT-141 work through the brain or through blood flow? Through the brain. PT-141 acts centrally on melanocortin receptors in hypothalamic and limbic circuits governing sexual motivation [1]. A randomized, double-blind fMRI study showed it alters central brain processing of erotic stimuli — direct evidence of a central, not vascular, mechanism [5]. This is the key contrast with blood-flow drugs. ## What is a melanocortin receptor agonist? A melanocortin receptor agonist is a molecule that activates the melanocortin receptors (MC1R-MC5R), a family of G-protein-coupled receptors that respond to hormones like alpha-MSH [1]. PT-141 is one such agonist, targeting the central MC4R/MC3R subtypes tied to sexual desire [1]. ## Does PT-141 increase testosterone? No. PT-141 does not act through the testosterone (HPG) axis and does not directly raise testosterone — a common misconception. It acts on central melanocortin receptors to influence sexual desire, an entirely separate pathway [1]. It is also not a PDE-5 inhibitor. ## How is PT-141 different from PDE-5 inhibitors? PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow. PT-141 acts centrally, on brain melanocortin receptors in circuits governing sexual desire and motivation [1]. One targets blood flow at the end organ; the other targets desire in the brain — different mechanisms, different effects [5]. ## What is the PT-141 dosage? The approved (label-attested) dose for HSDD in premenopausal women is 1.75 mg subcutaneously, as needed, with a ceiling of one dose per 24 hours and eight doses per month [7]. Research programs used different doses and routes. No dose is recommended here for any individual. ## How much PT-141 should I take? This site does not recommend a dose for any person — that is a clinical decision, not an editorial one. For context only, the approved drug's labeled dose is 1.75 mg subcutaneous as needed for HSDD in premenopausal women, with a one-dose-per-24-hours ceiling [7]. Research-grade material has no verified concentration. ## How much PT-141 to inject? No injection amount is recommended here. As a record, the FDA-approved label specifies a 1.75 mg subcutaneous dose, as needed, no more than once per 24 hours and no more than eight times per month, for the approved HSDD indication [7]. Reporting the label figure is not a dosing instruction. ## What is the PT-141 dosage for women? For the approved use in premenopausal women with HSDD, the labeled dose is 1.75 mg subcutaneous, as needed [7]. That dose came from the RECONNECT Phase 3 trials after Phase 2 dose-finding tested 0.75, 1.25, and 1.75 mg [3]. Use in postmenopausal women is not approved. ## How do you reconstitute PT-141? This site does not provide reconstitution or preparation instructions. The approved drug is supplied as a ready-to-use subcutaneous injection per its prescribing information [7]; it is not a reconstitute-it-yourself product. Research-grade powder sold as "PT-141" is unregulated, with no verified identity or concentration, so no preparation guidance is given here [7]. --- A clinical reading room for the PT-141 (bremelanotide) record, read under one desk lamp — the single approved use logged in crimson before anything else, the label figures kept apart from the study findings and both apart from the unverified reports, with no clinic behind the door and nothing here dosed, sourced, or sold.